Skip to content
HowShorted

CAPRICOR THERAPEUTICS, INC. short interest in 2021

In 2021, CAPRICOR THERAPEUTICS, INC.'s disclosed short interest ran from 3.74% of shares outstanding on 15 Jan 2021 to 2.80% on 31 Dec 2021, a change of -0.94 percentage points. The year's high was 9.92% on 30 Jun 2021 and its low 1.69% on 26 Feb 2021, averaging 4.59% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.78 days on 28 May 2021. Full history: CAPRICOR THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CAPRICOR THERAPEUTICS, INC. in 2021

2021 in figures

Start of year
3.74% (15 Jan 2021)
End of year
2.80% (31 Dec 2021)
Change
-0.94 pp
High
9.92% (30 Jun 2021)
Low
1.69% (26 Feb 2021)
Average
4.59%
Highest days to cover
11.78 (28 May 2021)
SEC filings marked
8

Every report in 2021

CAPRICOR THERAPEUTICS, INC. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20213.74%1.00
29 Jan 20213.38%1.00
12 Feb 20212.39%1.00
26 Feb 20211.69%1.00
15 Mar 20211.90%1.07results (8-K), 10-K filed
31 Mar 20214.12%2.90
15 Apr 20213.83%5.07
30 Apr 20215.00%1.16
14 May 20217.70%4.20results (8-K), 10-Q filed
28 May 20217.62%11.78
15 Jun 20218.44%8.59
30 Jun 20219.92%2.01
15 Jul 20219.42%10.92
30 Jul 20214.75%4.81
13 Aug 20213.25%5.14results (8-K), 10-Q filed
31 Aug 20212.91%3.43
15 Sep 20213.17%3.83
30 Sep 20215.09%1.00
15 Oct 20214.47%4.09
29 Oct 20213.95%7.23
15 Nov 20213.78%4.97results (8-K), 10-Q filed
30 Nov 20213.68%5.11
15 Dec 20213.24%3.40
31 Dec 20212.80%2.85

See also: CAPRICOR THERAPEUTICS, INC.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.